Unique ID issued by UMIN | UMIN000049135 |
---|---|
Receipt number | R000055909 |
Scientific Title | Ad-hoc analysis of factors related with efficacies and safeties of mogamulizumab single agent or VCAP/AMP/VECP/mogamulizumab combination therapy for adult T-cell leukemia/lymphoma patients based on clinical trials and research results. |
Date of disclosure of the study information | 2022/10/17 |
Last modified on | 2023/10/10 09:37:55 |
Analysis of factors related with efficacies and safeties of mogamulizumab treatments for adult T-cell leukemia/lymphoma patients.
Analysis of factors related with efficacies and safeties of mogamulizumab treatments for adult T-cell leukemia/lymphoma patients.
Ad-hoc analysis of factors related with efficacies and safeties of mogamulizumab single agent or VCAP/AMP/VECP/mogamulizumab combination therapy for adult T-cell leukemia/lymphoma patients based on clinical trials and research results.
Ad-hoc analysis of factors related with efficacies and safeties of mogamulizumab single agent or VCAP/AMP/VECP/mogamulizumab combination therapy for adult T-cell leukemia/lymphoma patients.
Japan | North America | South America |
Europe |
Adult T-cell leukemia/lymphoma
Hematology and clinical oncology |
Malignancy
NO
Investigate factors related with efficacies and safeties of mogamulizumab treatments for adult T-cell leukemia/lymphoma patients.
Others
Factors related with progression free survival. Duration of progression free survival and overall survival, proportions of best response rates, and incidence of adverse events based on the factors.
Not applicable
Progression free survival
Overall survival
Best response
Safety
Others,meta-analysis etc
Not applicable |
Not applicable |
Male and Female
Patients whose data was recorded participating the flowing clinical trials and clinical research:
Phase 2 clinical trial investigating mogamulizumab efficacy and safety for relapsed ATL patients
Phase 2 clinical trial comparing mogamulizumab efficacy and safety with investigator's choice for relapsed/refractory ATL patients
Phase 2 clinical trial comparing efficacy and safety of mLSG15+mogamulizumab combination therapy with mLSG15 alone for untreated ATL patients and following clinical research.
No specific criteria
151
1st name | Yukihiro |
Middle name | |
Last name | Nishio |
Kyowa Kirin Co., Ltd.
Medical Affairs
100-0004
1-9-2, Otemachi, Chiyoda-ku, Tokyo
03-5205-7200
ma.oncology.g.19@kyowakirin.com
1st name | Yukihiro |
Middle name | |
Last name | Nishio |
Kyowa Kirin Co., Ltd.
Medical Affairs
100-0004
1-9-2, Otemachi, Chiyoda-ku, Tokyo
03-5205-7200
ma.oncology.g.19@kyowakirin.com
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
Self funding
Research Ethical Review Committee of Kyowa Kirin Co., Ltd
1-9-2, Otemachi, Chiyoda-ku, Tokyo 100-0004, JAPAN
03-5205-7200
researchethics.fj@kyowakirin.com
NO
2022 | Year | 10 | Month | 17 | Day |
Unpublished
146
No longer recruiting
2022 | Year | 09 | Month | 26 | Day |
2022 | Year | 09 | Month | 21 | Day |
2022 | Year | 09 | Month | 26 | Day |
2024 | Year | 12 | Month | 31 | Day |
This study will use the data from clinical trials and clinical research conducted by Kyowa Kirin Co., Ltd.
2022 | Year | 10 | Month | 06 | Day |
2023 | Year | 10 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000055909
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |